Cochlear record revenue fails to impress investors
06 February, 2013 by Tim DeanCochlear (ASX:COH) has posted record revenue for the second half of 2012, with sales up 27%, although the share price tumbled over 9% following the news.
Metabolic eyes human trials for experimental osteoarthritis treatment
06 February, 2013 by Tim DeanA positive result from an animal trial of Calzada (ASX:CZD) subsidiary Metabolic Pharmaceuticals’ osteoarthritis treatment could lead to phase II human trials beginning soon.
TGA consults on proposed changes to pre-market assessment for medical devices
05 February, 2013 by AusBiotechThe Therapeutic Goods Administration has proposed changes to the pre-market assessment requirements in its consultation paper released in January.
BioDiem expanding indications for BDM-I
04 February, 2013 by Dylan Bushell-EmblingBioDiem (ASX:BDM) is extending a research agreement with US-based NIAID to cover the evaluation of antimicrobial BDM-I in tuberculosis and serious fungal infections.
Alchemia progresses with colorectal cancer trial
04 February, 2013 by Dylan Bushell-EmblingAlchemia (ASX:ACL) has enrolled the 390th patient for its phase III trial of HA-Irinotecan in metastatic colorectal cancer and expects to reach the primary endpoint in early 2014.
PolyNovo to file with FDA to seek NovoSorb in US
04 February, 2013 by Tim DeanCalzada (ASX:CZD) subsidiary PolyNovo will seek marketing approval in the US for NovoSorb, its dressing for hard-to-heal pressure sores.
Pharmaxis stock plummets on negative FDA recommendation
31 January, 2013 by Tim DeanPharmaxis (ASX:PXS) stock has dropped 40% following a negative recommendation from an expert panel that Bronchitol should be approved by the FDA.
AtCor forecasts profit in 2013
31 January, 2013 by Tim DeanMedical device manufacturer AtCor (ASX:ACG) expects to report a profit in this financial year following strong sales of its SphygmoCor diagnostic device.
The rise of smartphone health and medical apps
31 January, 2013 by Michael Sutton and Megan FraserHealth and medical smartphone apps can help improve the management of acute and chronic conditions and provide more personalised medical treatment.
Mesoblast gets FDA all-clear for arthritis stem cell trial
30 January, 2013 by Dylan Bushell-EmblingThe FDA has approved Mesoblast’s (ASX:MSB) application to conduct a phase II trial of its mesenchymal precursor cells to treat rheumatoid arthritis.
State of the industry to be gauged by its leaders in annual survey
30 January, 2013 by AusBiotechAusBiotech is pleased to once again conduct the annual CEO Industry Position Survey 2013 to get a comprehensive view of the Australian biotechnology sector.
Major medtech conference moves to Victoria
30 January, 2013 by AusBiotechAusMedtech 2013, Australia’s premier medical technology conference, will be held in Melbourne for the first time on 15-16 May, with the support of the state government of Victoria.
Biotechs up after All Ordinaries surge
30 January, 2013 by Tim DeanLife science stocks have enjoyed a boost alongside the broader share market, with stocks such as CSL (ASX:CSL) hitting historic highs.
ResMed revenues up thanks to strong sales
30 January, 2013 by Tim DeanResMed (ASX:RMD) has seen revenues increase by 13% for the December quarter year on year with a dividend coming in February.
FDA panel to vote on Pharmaxis’s NDA
30 January, 2013 by Dylan Bushell-EmblingAn independent advisory panel will vote today on whether to recommend the US FDA approve Pharmaxis’s (ASX:PSX) NDA for Bronchitol as a cystic fibrosis treatment.
